Arthritis Relief Plus Ltd (ARP) has developed, patented and successfully tested in a Phase III Clinical Trial, a novel, botanical, topical product for the treatment of osteoarthritis. ARP has grown to where it is today with the support of a core of dedicated stakeholders, who have worked diligently to develop the product formulation, protect the intellectual property, register trademarks and oversee the completion of a Phase III clinical study to support evidence based marketing claims. It is anticipated that the Acteev® technology could potentially provide significant cost savings for the community by delaying the need for surgery and avoiding the medical intervention required to treat side effects of Non-Steroidal Anti Inflammatory Drugs (NSAIDS) in many cases.